Literature DB >> 16786466

[Electrical and pharmacological strategies for early cardioversion of atrial fibrillation].

M Linhart1, T Lewalter.   

Abstract

Cardioversion of atrial fibrillation as an element of rhythm control strategy is indicated in patients with first episode of atrial fibrillation, hemodynamic instability, recurrent atrial fibrillation with low probability of spontaneous conversion, or severe symptoms. Early cardioversion is performed within 48 h of onset of atrial fibrillation. The best point in time is still unknown. It can be performed by pharmacological, or, preferentially, by electrical cardioversion. The advantages of electrical cardioversion are higher efficacy and no proarrhythmic risk, however, short time general anaesthesia is needed. Electrical cardioversion is most effective when biphasic shocks are delivered. For pharmacological cardioversion, several antiarrhythmic drugs are available which have to be considered individually. Thromboembolic risk does not differ between the two methods. Early cardioversion and maintenance of sinus rhythm is most effective in atrial fibrillation of short duration, normal left atrial size and no or only mild structural heart disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16786466     DOI: 10.1007/s00399-006-0514-0

Source DB:  PubMed          Journal:  Herzschrittmacherther Elektrophysiol        ISSN: 0938-7412


  39 in total

1.  A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation.

Authors:  Isabelle C Van Gelder; Vincent E Hagens; Hans A Bosker; J Herre Kingma; Otto Kamp; Tsjerk Kingma; Salah A Said; Julius I Darmanata; Alphons J M Timmermans; Jan G P Tijssen; Harry J G M Crijns
Journal:  N Engl J Med       Date:  2002-12-05       Impact factor: 91.245

2.  A trial of self-adhesive patch electrodes and hand-held paddle electrodes for external cardioversion of atrial fibrillation (MOBIPAPA).

Authors:  Paulus Kirchhof; Gerold Mönnig; Kristina Wasmer; Achim Heinecke; Günter Breithardt; Lars Eckardt; Dirk Böcker
Journal:  Eur Heart J       Date:  2005-02-25       Impact factor: 29.983

3.  Amiodarone infusion in the treatment of acute atrial fibrillation or flutter: high versus low dose treatment.

Authors:  V Tuseth; H J Jaatun; K Dickstein
Journal:  Heart       Date:  2005-07       Impact factor: 5.994

Review 4.  [Pharmacotherapy of supraventricular arrhythmias. What comes, what remains, what goes?].

Authors:  T Lewalter; G Nickenig
Journal:  Internist (Berl)       Date:  2006-01       Impact factor: 0.743

5.  ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation): developed in Collaboration With the North American Society of Pacing and Electrophysiology.

Authors:  V Fuster; L E Rydén; R W Asinger; D S Cannom; H J Crijns; R L Frye; J L Halperin; G N Kay; W W Klein; S Lévy; R L McNamara; E N Prystowsky; L S Wann; D G Wyse; R J Gibbons; E M Antman; J S Alpert; D P Faxon; V Fuster; G Gregoratos; L F Hiratzka; A K Jacobs; R O Russell; S C Smith; W W Klein; A Alonso-Garcia; C Blomström-Lundqvist; G De Backer; M Flather; J Hradec; A Oto; A Parkhomenko; S Silber; A Torbicki
Journal:  J Am Coll Cardiol       Date:  2001-10       Impact factor: 24.094

6.  Risk of initiating antiarrhythmic drug therapy for atrial fibrillation in patients admitted to a university hospital.

Authors:  W H Maisel; K M Kuntz; S C Reimold; T H Lee; E M Antman; P L Friedman; W G Stevenson
Journal:  Ann Intern Med       Date:  1997-08-15       Impact factor: 25.391

7.  Amiodarone versus sotalol for atrial fibrillation.

Authors:  Bramah N Singh; Steven N Singh; Domenic J Reda; X Charlene Tang; Becky Lopez; Crystal L Harris; Ross D Fletcher; Satish C Sharma; J Edwin Atwood; Alan K Jacobson; H Daniel Lewis; Dennis W Raisch; Michael D Ezekowitz
Journal:  N Engl J Med       Date:  2005-05-05       Impact factor: 91.245

8.  Outpatient treatment of recent-onset atrial fibrillation with the "pill-in-the-pocket" approach.

Authors:  Paolo Alboni; Giovanni L Botto; Nicola Baldi; Mario Luzi; Vitantonio Russo; Lorella Gianfranchi; Paola Marchi; Massimo Calzolari; Alberto Solano; Raffaele Baroffio; Germano Gaggioli
Journal:  N Engl J Med       Date:  2004-12-02       Impact factor: 91.245

9.  Embolic complications of direct current cardioversion of atrial arrhythmias: association with low intensity of anticoagulation at the time of cardioversion.

Authors:  Mark M Gallagher; Brian J Hennessy; Nils Edvardsson; Ceara M Hart; Muriel S Shannon; Owen A Obel; Naab M Al-Saady; A John Camm
Journal:  J Am Coll Cardiol       Date:  2002-09-04       Impact factor: 24.094

10.  Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats.

Authors:  M C Wijffels; C J Kirchhof; R Dorland; M A Allessie
Journal:  Circulation       Date:  1995-10-01       Impact factor: 29.690

View more
  2 in total

Review 1.  [New antiarrhythmic drugs for therapy of atrial fibrillation: I. Ion channel blockers].

Authors:  U Ravens; E Wettwer; U Schotten; R Wessel; D Dobrev
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2006-06

2.  [New aspects of atrial fibrillation therapy].

Authors:  U Ravens; D Dobrev; A Goette
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2006-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.